Core Viewpoint - Agilent Technologies is expected to report quarterly earnings of $1.27 per share, a 4.1% increase year-over-year, with revenues projected at $1.63 billion, reflecting a 3.3% increase compared to the same period last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.1% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Estimates by End Markets - Revenue by End Markets- Diagnostics and Clinical is estimated at $247.93 million, a year-over-year increase of 3.7% [5]. - Revenue by End Markets- Chemical and Advanced Materials is projected to reach $370.20 million, reflecting a 2.3% increase from the previous year [5]. - Revenue by End Markets- Food is expected to be $146.05 million, indicating a 5.1% year-over-year change [5]. - Revenue by End Markets- Academia and Government is forecasted at $145.13 million, suggesting a 4.4% increase year-over-year [6]. - Net Revenue- Life Sciences and Applied Markets Group is anticipated to be $628.72 million, showing a significant decline of 16.6% year-over-year [6]. - Net Revenue- Agilent Crosslab Group is projected at $697.53 million, indicating a substantial increase of 73.5% year-over-year [6]. - Revenue by End Markets- Pharmaceutical is expected to reach $572.63 million, reflecting a 5.7% increase from the prior year [7]. - Revenue by End Markets- Environmental and Forensics is estimated at $159.54 million, indicating a 5% increase year-over-year [7]. Stock Performance - Over the past month, Agilent shares have returned 3.7%, compared to a 13.4% increase in the Zacks S&P 500 composite [7]. - Agilent currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7].
Curious about Agilent (A) Q2 Performance? Explore Wall Street Estimates for Key Metrics